Editorial: Toward Personalized Treatment for Systemic Juvenile Idiopathic Arthritis.
作者信息
Vastert Sebastiaan J, Nigrovic Peter A
机构信息
University Medical Center Utrecht, Utrecht, The Netherlands.
Brigham and Women's Hospital and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
Arthritis Rheumatol. 2018 Aug;70(8):1172-1174. doi: 10.1002/art.40501. Epub 2018 Jun 29.
Abstract
摘要
相似文献
1
Editorial: Toward Personalized Treatment for Systemic Juvenile Idiopathic Arthritis.
Arthritis Rheumatol. 2018 Aug;70(8):1172-1174. doi: 10.1002/art.40501. Epub 2018 Jun 29.
2
A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis.
Arthritis Rheumatol. 2019 Jul;71(7):1030-1033. doi: 10.1002/art.40867. Epub 2019 May 27.
3
Blocking IL-1 in systemic inflammation.
J Exp Med. 2005 May 2;201(9):1355-9. doi: 10.1084/jem.20050640.
4
Association of interleukin-1 family gene polymorphisms with juvenile idiopathic arthritis in Iranian population.
Allergol Immunopathol (Madr). 2016 Nov-Dec;44(6):542-546. doi: 10.1016/j.aller.2016.07.002. Epub 2016 Oct 4.
5
Testing the Model for Predicting Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
J Rheumatol. 2019 Oct;46(10):1422-1424. doi: 10.3899/jrheum.190238. Epub 2019 Jun 15.
6
Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.
Pediatr Ann. 2015 Jun;44(6):e142-7. doi: 10.3928/00904481-20150611-09.
7
Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?
Arthritis Rheumatol. 2014 Jun;66(6):1405-13. doi: 10.1002/art.38615.
8
The systemic-onset variant of juvenile idiopathic arthritis needs to be recorded as an autoinflammatory syndrome: comment on the review by Nigrovic.
Arthritis Rheumatol. 2014 Sep;66(9):2645. doi: 10.1002/art.38698.
9
Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
J Clin Rheumatol. 2009 Jun;15(4):161-4. doi: 10.1097/RHU.0b013e3181a4f459.
10
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
J Rheumatol. 2004 Oct;31(10):2071-5.
引用本文的文献
1
Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis.
Rheumatology (Oxford). 2023 Feb 23;62(SI2):SI170-SI180. doi: 10.1093/rheumatology/keac299.
2
Costs of Hospital-Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System.
Arthritis Care Res (Hoboken). 2022 Oct;74(10):1585-1592. doi: 10.1002/acr.24621. Epub 2022 Jul 7.
3
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
Ann Rheum Dis. 2020 Aug;79(8):1090-1097. doi: 10.1136/annrheumdis-2020-217155. Epub 2020 May 13.
本文引用的文献
1
High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction.
Nat Genet. 2018 Aug;50(8):1180-1188. doi: 10.1038/s41588-018-0159-z. Epub 2018 Jul 16.
2
IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.
Arthritis Rheumatol. 2018 Aug;70(8):1319-1330. doi: 10.1002/art.40498. Epub 2018 Jun 28.
3
Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Clin Trials. 2018 Jun;15(3):268-277. doi: 10.1177/1740774518761367. Epub 2018 Mar 15.
4
Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications.
Ann Rheum Dis. 2017 May;76(5):906-913. doi: 10.1136/annrheumdis-2016-210324. Epub 2016 Dec 7.
5
HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15970-5. doi: 10.1073/pnas.1520779112. Epub 2015 Nov 23.
6
Advances in biomarkers for paediatric rheumatic diseases.
Nat Rev Rheumatol. 2015 May;11(5):265-75. doi: 10.1038/nrrheum.2014.208. Epub 2014 Dec 16.
7
Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
Arthritis Rheumatol. 2014 Apr;66(4):1034-43. doi: 10.1002/art.38296.
8
Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?
Arthritis Rheumatol. 2014 Jun;66(6):1405-13. doi: 10.1002/art.38615.
9
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
N Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099.
10
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
N Engl J Med. 2012 Dec 20;367(25):2385-95. doi: 10.1056/NEJMoa1112802.
Zotero 插件